Wacker Biotech Collaborates with RNAV8 Bio on mRNA Therapeutics Development

Analytical data key ingredient to successful CDMO partnerships, says panel at BioProcess International West

Analytical data key ingredient to successful CDMO partnerships, says panel of experts in biopharma and biotechnology at BioProcess International West in San Diego

Wacker Biotech, a contract manufacturing organization (CDMO) for biopharmaceuticals and a wholly owned subsidiary of Wacker Chemie AG, has announced a strategic collaboration with RNAV8 Bio, a Boston-based pioneer in mRNA engineering. The goal of the collaboration is to accelerate the development and production of...

Wacker Biotech Collaborates with RNAV8 Bio on mRNA Therapeutics Development

Wacker Biotech, a CDMO, began a strategic collaboration with Boston-based RNAV8 Bio aimed at progressing the development and production of mRNA-based advanced therapies for the biopharma industry. This new partnership combines Wacker Biotech’s expertise in pDNA/mRNA manufacturing and lipid nanoparticle (LNP) formulation with RNAV8 Bio’s mRNA engineering toolkit, which enhances the noncoding sequences of mRNA strands (UTRs), according to Philippe…